Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEDTRONIC TREATMENT IND FOR BACLOFEN IN SYNCHROMED IMPLANTABLE PUMP

Executive Summary

MEDTRONIC TREATMENT IND FOR BACLOFEN IN SYNCHROMED IMPLANTABLE PUMP approved by FDA March 8. The first to involve a medical device, the Treatment IND covers use of the drug/device in patients with intractable spinal spasticity (caused by spinal cord injury or multiple sclerosis) that is resistant to standard therapy with oral baclofen (Ciba-Geigy's Lioresal). Ciba-Geigy will supply the baclofen solution, which it developed specifically for use in the Medtronic pump, free to patients in the Treatment IND. Minneapolis-based Medtronic, the official sponsor of the Treatment IND, will handle all other aspects of the expanded use investigational program. Medtronic plans to publicly announce details of the Treatment IND, including the commencement date and whether the firm will seek cost recovery for its device, early in the week of March 19. * Medtronic estimates that the potential U.S. treatment population for the drug/device combination is between 20,000 and 40,000. The drug/device treatment has orphan status and its development was supported by a grant from FDA's Office of Orphan Product Development. To date, the baclofen/SynchroMed pump therapy has been tested in about 150 patients. The combination has been in clinicals at Chicago's Rush-Presbyterian-St. Luke Medical Center, under the direction of principal investigator Richard Penn, MD. A double-blind cross-over study in 20 patients, conducted by Penn and reported in the June 8, 1989 New England Journal of Medicine, found that intrathecal infusion with the SynchroMed system achieved a ten-times higher level of baclofen in cerebrospinal fluid at a dose 100 times smaller than the oral treatment, greatly reducing the drug's toxicity. * In addition to the Treatment IND, Medtronic will be taking responsibility for obtaining regulatory approvals for the solution form of baclofen and for use of the agent in the implantable pump, which is already approved for use with several chemotherapeutic agents. Once approved, Ciba-Geigy will provide Medtronic with the baclofen solution under a purchasing agreement.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel